Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells $510,252.77 in Stock

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 39,341 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Trading Up 11.6%

REPL traded up $1.59 during midday trading on Wednesday, reaching $15.24. 8,269,132 shares of the company’s stock traded hands, compared to its average volume of 5,046,735. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $15.68. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The firm has a fifty day moving average of $10.34 and a two-hundred day moving average of $7.64. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.51 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, equities analysts anticipate that Replimune Group, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

REPL has been the subject of several research reports. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Finally, Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.86.

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company’s liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering
• Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing
• Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice

Hedge Funds Weigh In On Replimune Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in REPL. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group in the 4th quarter worth about $29,000. CWM LLC increased its stake in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after acquiring an additional 2,886 shares in the last quarter. Allworth Financial LP purchased a new position in Replimune Group during the 2nd quarter valued at about $62,000. Essential Partners LLC boosted its stake in Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.